An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) Administered in Healthy Subjects

Trial Profile

An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) Administered in Healthy Subjects

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Raxibacumab (Primary)
  • Indications Anthrax
  • Focus Pharmacodynamics
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 30 Dec 2013 Planned number of patients changed from 20 to NULL.
    • 30 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top